---
title: "12 Health Care Stocks Moving In Thursday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292198271.md"
description: "In Thursday's pre-market session, healthcare stocks showed significant volatility. Gainers included Virax Biolabs (VRAX) up 134%, Alnylam Pharmaceuticals (ALNY) up 17.7%, and Bluejay Diagnostics (BJDX) up 14.92%. Conversely, losers featured Ionis Pharmaceuticals (IONS) down 21.9%, Catheter Precision (VTAK) down 18.89%, and Aptevo Therapeutics (APVO) down 14.45%."
datetime: "2026-07-09T12:05:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292198271.md)
  - [en](https://longbridge.com/en/news/292198271.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292198271.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Thursday's Pre-Market Session

### Gainers

-   **Virax Biolabs Group** (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million.
-   **Alnylam Pharmaceuticals** (NASDAQ:ALNY) stock moved upwards by 17.7% to $380.76. The market value of their outstanding shares is at $43.1 billion.
-   **Bluejay Diagnostics** (NASDAQ:BJDX) shares rose 14.92% to $1.54. The company's market cap stands at $1.3 million.
-   **BridgeBio Pharma** (NASDAQ:BBIO) shares rose 12.66% to $88.25. The market value of their outstanding shares is at $15.3 billion.
-   **VivoSim Labs** (NASDAQ:VIVS) stock increased by 11.16% to $0.87. The company's market cap stands at $2.2 million.
-   **Oncolytics Biotech** (NASDAQ:ONCY) stock increased by 9.8% to $0.87. The company's market cap stands at $94.5 million.

### Losers

-   **Ionis Pharmaceuticals** (NASDAQ:IONS) shares decreased by 21.9% to $66.0 during Thursday's pre-market session. The company's market cap stands at $13.9 billion.
-   **Catheter Precision** (AMEX:VTAK) shares declined by 18.89% to $1.11. The company's market cap stands at $4.9 million.
-   **Aptevo Therapeutics** (NASDAQ:APVO) shares decreased by 14.45% to $3.85. The company's market cap stands at $5.6 million.
-   **Tvardi Therapeutics** (NASDAQ:TVRD) shares decreased by 9.4% to $4.53. The market value of their outstanding shares is at $46.9 million.
-   **AEON Biopharma** (AMEX:AEON) shares declined by 8.5% to $0.64. The market value of their outstanding shares is at $18.4 million.
-   **Shuttle Pharmaceuticals** (NASDAQ:SHPH) stock declined by 8.41% to $3.27. The company's market cap stands at $2.0 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [APVO.US](https://longbridge.com/en/quote/APVO.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [VTAK.US](https://longbridge.com/en/quote/VTAK.US.md)
- [BJDX.US](https://longbridge.com/en/quote/BJDX.US.md)
- [VRAX.US](https://longbridge.com/en/quote/VRAX.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [VIVS.US](https://longbridge.com/en/quote/VIVS.US.md)
- [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md)
- [TVRD.US](https://longbridge.com/en/quote/TVRD.US.md)
- [AEON.US](https://longbridge.com/en/quote/AEON.US.md)
- [SHPH.US](https://longbridge.com/en/quote/SHPH.US.md)

## Related News & Research

- [Alnylam Pharmaceuticals (ALNY) Gains Attention After Fresh RNAi Data, Is It 33% Undervalued?](https://longbridge.com/en/news/298836244.md)
- [Catheter Precision subsidiary Flyte partners with Christian Cowan for New York Fashion Week](https://longbridge.com/en/news/298639797.md)
- [Trump Is Still Very Much Operating Off ‘Concepts’ Of A Health Care Plan](https://longbridge.com/en/news/298872418.md)
- [Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture](https://longbridge.com/en/news/299024235.md)
- [Stifel Nicolaus Keeps Their Hold Rating on Sionna Therapeutics, Inc. (SION)](https://longbridge.com/en/news/299037622.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**